PMC Bone Marrow Failure Syndromes Panel

Up to 170 genes Turn around Time: 10 business days
Order a Kit:

Testing Kit Request Form

New Provider:

Please fill out the form:
Provider Registration Form

Contact:

info@pmcdx.com

Test Description

PMC Bone Marrow Failure Syndromes Panel analyzes genes involved in bone marrow failure (BMF). Due to overlapping clinical features of hereditary susceptibility conditions| utilizing a comprehensive panel test enables a thorough evaluation of potential genes for individuals with similar clinical symptoms. Genetic testing can help establishing accurate diagnosis| targeted treatment| prognosis prediction| family planning and preventive measures. This test identifies heritable germline mutations| and not intended for somatic mutations.

  • Associated Conditions
    • 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia (MEGCANN)
    • Acute myeloid leukemia, familial
    • Amegakaryocytic thrombocytopenia
    • Anemia, dyserythropoietic congenital
    • Anemia, sideroblastic 2, pyridoxine-refractory
    • Anemia, sideroblastic, Protoporphyria, erythropoietic
    • Anemia, without thrombocytopenia, Thrombocytopenia with beta-thalessemia,, Dyserythropoietic anemia with thrombocytopenia
  • Methodology

    Targeted Exome/ Slice Exome (Next Generation Sequencing including Copy Number Variation)

  • Assay Information
    • ATR: Deletion/duplication analysis is not offered for exon 34. Sequencing analysis for exons 34 includes only cds +/- 10 bp.
    • BRCA1: Sequence analysis includes +/- 20 base pairs of adjacent intronic sequence.
    • RPL19: Sequencing analysis for exons 6 includes only cds +/- 10 bp.
    • FANCL: Sequencing analysis for exons 4| 10 includes only cds +/- 10 bp.
    • FANCD2: Deletion/duplication analysis is not offered for exons 14-17| 22 and sequencing analysis is not offered for exons 15-17. Sequencing analysis for exons 6| 14| 18| 20| 23| 25| 34 includes only cds +/- 10 bp.
    • GFI1: Sequencing analysis for exons 6 includes only cds +/- 0 bp.
    • AK2: Deletion/duplication and sequencing analysis is not offered for exon 6.
  • Limitations

    All sequencing technologies have limitations. A negative result from this analysis does not rule out a possible genetic diagnosis as some variants may not be detected by this test. This test is not designed to detect low level mosaicism, structural rearrangements, indels >40bp, deep intronic variants of unknown clinical significance, or large cytogenetic CNVs. Certain inherent qualities of the human genome, for example repetitive regions/homopolymers, GC rich, pseudogenes, and rare polymorphisms, pose significant technical challenges such as sequence misalignment that may potentially impact the accuracy of the results. False negative results may also occur in the setting of allogeneic bone marrow, stem cell transplantation, active or chronic hematologic conditions, recent blood transfusions, suboptimal DNA quality or PCR trace contamination. Other potential sources of error include sample mix-ups and clerical issues.

  • References
    • 1. Richards S et al. Genetics in medicine. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. 2015 May;17(5):405-24 (PMID: 25741868)
    • 2. GnomAD (gnomAD)
    • 3. CSPEC (ClinGen variant classification rules registry) Criteria Specification Registry
    • 4. Normal copy number variation in healthy individuals database of genomic variants: http://dgv.tcag.ca/dgv/app/home
  • Tagged Genes

    Primary panel:

    170 genes selected